First Evaluation of Temporal and Spatial Fractionation in Proton Minibeam Radiation Therapy of Glioma-Bearing Rats.

high-grade gliomas proton minibeam radiation therapy temporal fractionation

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
28 Sep 2021
Historique:
received: 02 09 2021
revised: 22 09 2021
accepted: 23 09 2021
entrez: 13 10 2021
pubmed: 14 10 2021
medline: 14 10 2021
Statut: epublish

Résumé

(1) Background: Proton minibeam radiation therapy (pMBRT) is a new radiotherapy technique using spatially modulated narrow proton beams. pMBRT results in a significantly reduced local tissue toxicity while maintaining or even increasing the tumor control efficacy as compared to conventional radiotherapy in small animal experiments. In all the experiments performed up to date in tumor bearing animals, the dose was delivered in one single fraction. This is the first assessment on the impact of a temporal fractionation scheme on the response of glioma-bearing animals to pMBRT. (2) Methods: glioma-bearing rats were irradiated with pMBRT using a crossfire geometry. The response of the irradiated animals in one and two fractions was compared. An additional group of animals was also treated with conventional broad beam irradiations. (3) Results: pMBRT delivered in two fractions at the biological equivalent dose corresponding to one fraction resulted in the highest median survival time, with 80% long-term survivors free of tumors. No increase in local toxicity was noted in this group with respect to the other pMBRT irradiated groups. Conventional broad beam irradiations resulted in the most severe local toxicity. (4) Conclusion: Temporal fractionation increases the therapeutic index in pMBRT and could ease the path towards clinical trials.

Identifiants

pubmed: 34638352
pii: cancers13194865
doi: 10.3390/cancers13194865
pmc: PMC8507607
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : INCA
ID : SIRIC 2018-2022 (INCa-DGOS-Inserm_12554)
Organisme : European Research Council
ID : 817908
Pays : International

Références

Br J Radiol. 2020 Mar;93(1107):20190578
pubmed: 31868523
Ecancermedicalscience. 2017 Nov 30;11:785
pubmed: 29225692
Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1570-80
pubmed: 16580506
Cureus. 2020 Jan 26;12(1):e6777
pubmed: 32117663
Cancers (Basel). 2020 Feb 25;12(3):
pubmed: 32106397
Med Phys. 2012 Nov;39(11):6818-37
pubmed: 23127075
Br J Radiol. 2002 May;75(893):460-3
pubmed: 12036841
Med Phys. 2013 Mar;40(3):031712
pubmed: 23464307
Sci Rep. 2018 Nov 7;8(1):16479
pubmed: 30405188
J Synchrotron Radiat. 2009 Jul;16(Pt 4):587-90
pubmed: 19535875
J Natl Med Assoc. 1990 Dec;82(12):833-6
pubmed: 2280428
Int J Radiat Biol. 1989 Dec;56(6):1045-8
pubmed: 2574214
Cancers (Basel). 2020 Sep 17;12(9):
pubmed: 32957691
Phys Med. 2019 Aug;64:195-203
pubmed: 31515020
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Toxicol Pathol. 2013;41(7):1028-48
pubmed: 23475559
Phys Med Biol. 2005 Jul 7;50(13):3103-11
pubmed: 15972983
Sci Rep. 2017 Dec 11;7(1):17295
pubmed: 29229965
Med Phys. 2015 Dec;42(12):7108-13
pubmed: 26632064
Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):76-83
pubmed: 32805301
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):234-241
pubmed: 26692028
Br J Radiol. 2019 Mar;92(1095):20180466
pubmed: 30359081
Nat Rev Cancer. 2004 Sep;4(9):737-47
pubmed: 15343280
Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):266-271
pubmed: 30703513
Radiat Res. 2020 Dec 1;194(6):715-723
pubmed: 32991712
J Neurosurg. 1999 Aug;91(2):251-60
pubmed: 10433313
Med Phys. 2018 Nov;45(11):5305-5316
pubmed: 30311639
Radiat Environ Biophys. 2013 Mar;52(1):123-33
pubmed: 23271171
Sci Rep. 2020 Aug 11;10(1):13511
pubmed: 32782370
Sci Rep. 2017 Oct 31;7(1):14403
pubmed: 29089533

Auteurs

Annaïg Bertho (A)

Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.
Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.

Ramon Ortiz (R)

Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.
Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.

Marjorie Juchaux (M)

Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.
Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.

Cristèle Gilbert (C)

Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.
Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.

Charlotte Lamirault (C)

Translational Research Department, Institut Curie, Experimental Radiotherapy Platform, Université Paris Saclay, 91400 Orsay, France.

Frederic Pouzoulet (F)

Translational Research Department, Institut Curie, Experimental Radiotherapy Platform, Université Paris Saclay, 91400 Orsay, France.

Laura Polledo (L)

AnaPath GmbH, AnaPath Services, Hammerstrasse 49, 4410 Liestal, Switzerland.

Alethea Liens (A)

AnaPath GmbH, AnaPath Services, Hammerstrasse 49, 4410 Liestal, Switzerland.

Nils Warfving (N)

AnaPath GmbH, AnaPath Services, Hammerstrasse 49, 4410 Liestal, Switzerland.

Catherine Sebrie (C)

CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, BIOMAPS Université Paris-Saclay, 91401 Orsay, France.

Laurène Jourdain (L)

CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, BIOMAPS Université Paris-Saclay, 91401 Orsay, France.

Annalisa Patriarca (A)

Centre de Protonthérapie d'Orsay, Radiation Oncology Department, Campus Universitaire, Institut Curie, PSL Research University, 91898 Orsay, France.

Ludovic de Marzi (L)

Centre de Protonthérapie d'Orsay, Radiation Oncology Department, Campus Universitaire, Institut Curie, PSL Research University, 91898 Orsay, France.
Institut Curie, Campus Universitaire, PSL Research University, University Paris Saclay, INSERM LITO, 91898 Orsay, France.

Yolanda Prezado (Y)

Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.
Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.

Classifications MeSH